Literature DB >> 31470930

Design and Challenges of Radiopharmaceuticals.

Koen Vermeulen1, Mathilde Vandamme1, Guy Bormans2, Frederik Cleeren1.   

Abstract

This review describes general concepts with regard to radiopharmaceuticals for diagnostic or therapeutic applications that help to understand the specific challenges encountered during the design, (radio)synthesis, in vitro and in vivo evaluation and clinical translation of novel radiopharmaceuticals. The design of a radiopharmaceutical requires upfront decisions with regard to combining a suitable vector molecule with an appropriate radionuclide, considering the type and location of the molecular target, the desired application, and the time constraints imposed by the relatively short half-life of radionuclides. Well-designed in vitro and in vivo experiments allow nonclinical validation of radiotracers. Ultimately, in combination with a limited toxicology package, the radiotracer becomes a radiopharmaceutical for clinical evaluation, produced in compliance with regulatory requirements for medicines for intravenous (IV) injection.
Copyright © 2019. Published by Elsevier Inc.

Mesh:

Substances:

Year:  2019        PMID: 31470930     DOI: 10.1053/j.semnuclmed.2019.07.001

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  12 in total

1.  [18F]BIBD-181: A Novel Positron Emission Tomography Tracer Specific for Synaptic Vesicle Glycoprotein 2A.

Authors:  Zeng Jiang; Xuebo Cheng; Hualong Chen; Wei Zheng; Yuli Sun; Ziyue Yu; Tingyu Yang; Lu Zhang; Di Fan; Zhihao Yang; Yajing Liu; Lin Ai; Zehui Wu
Journal:  ACS Med Chem Lett       Date:  2022-03-30       Impact factor: 4.632

Review 2.  Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.

Authors:  Louis Lauwerys; Evelien Smits; Tim Van den Wyngaert; Filipe Elvas
Journal:  Biomedicines       Date:  2022-05-05

3.  High-Efficiency Cationic Labeling Algorithm of Macroaggregated Albumin with 68Gallium.

Authors:  Uğur Ayşe; Gültekin Aziz; Yüksel Doğangün
Journal:  Nucl Med Mol Imaging       Date:  2021-02-10

Review 4.  Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside.

Authors:  Stephen Ahenkorah; Irwin Cassells; Christophe M Deroose; Thomas Cardinaels; Andrew R Burgoyne; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

Review 5.  Artificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development:: In Silico Smart Molecular Design.

Authors:  Bahar Ataeinia; Pedram Heidari
Journal:  PET Clin       Date:  2021-08-05

6.  Automated GMP compliant production of [18F]AlF-NOTA-octreotide.

Authors:  Térence Tshibangu; Christopher Cawthorne; Kim Serdons; Elin Pauwels; Willy Gsell; Guy Bormans; Christophe M Deroose; Frederik Cleeren
Journal:  EJNMMI Radiopharm Chem       Date:  2020-01-29

7.  Pediatric Nuclear Medicine Examinations and Subsequent Risk of Neoplasm: A Nationwide Population-Based Cohort Study.

Authors:  Mei-Kang Yuan; Shih-Chieh Chang; Mei-Chun Yuan; Ning-Ping Foo; Shan-Ho Chan; Shyh-Yau Wang; Cheng-Li Lin; Chung-Y Hsu; Chia-Hung Kao
Journal:  Front Med (Lausanne)       Date:  2021-12-20

Review 8.  Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.

Authors:  Xu Zhou; Linlin Dong; Langtao Shen
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411

9.  3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals.

Authors:  Stephen Ahenkorah; Erika Murce; Christopher Cawthorne; Jessica Pougoue Ketchemen; Christophe M Deroose; Thomas Cardinaels; Yann Seimbille; Humphrey Fonge; Willy Gsell; Guy Bormans; Maarten Ooms; Frederik Cleeren
Journal:  Theranostics       Date:  2022-08-08       Impact factor: 11.600

10.  Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals.

Authors:  Marianna Tosato; Mattia Asti; Marco Dalla Tiezza; Laura Orian; Daniel Häussinger; Raphael Vogel; Ulli Köster; Mikael Jensen; Alberto Andrighetto; Paolo Pastore; Valerio Di Marco
Journal:  Inorg Chem       Date:  2020-07-13       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.